Barclays PLC Buys 63,402 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

Barclays PLC grew its stake in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 190.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 96,623 shares of the company's stock after purchasing an additional 63,402 shares during the period. Barclays PLC owned approximately 0.23% of SI-BONE worth $1,350,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of SIBN. FMR LLC raised its position in shares of SI-BONE by 103.6% in the 3rd quarter. FMR LLC now owns 2,354 shares of the company's stock worth $33,000 after acquiring an additional 1,198 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in SI-BONE in the second quarter worth $61,000. Walleye Capital LLC bought a new position in SI-BONE in the third quarter worth $144,000. Arizona State Retirement System lifted its position in SI-BONE by 9.0% during the second quarter. Arizona State Retirement System now owns 10,921 shares of the company's stock valued at $141,000 after buying an additional 903 shares during the period. Finally, Deerfield Management Company L.P. Series C bought a new stake in shares of SI-BONE during the 2nd quarter valued at $151,000. Hedge funds and other institutional investors own 98.11% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SIBN. Needham & Company LLC reissued a "buy" rating and set a $19.00 price target on shares of SI-BONE in a research report on Monday. Truist Financial lifted their target price on shares of SI-BONE from $16.00 to $18.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SI-BONE has an average rating of "Buy" and an average target price of $23.00.

Insiders Place Their Bets

In related news, CFO Anshul Maheshwari sold 2,439 shares of SI-BONE stock in a transaction on Monday, November 18th. The shares were sold at an average price of $12.68, for a total transaction of $30,926.52. Following the transaction, the chief financial officer now owns 194,623 shares in the company, valued at approximately $2,467,819.64. The trade was a 1.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Laura Francis sold 10,048 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $12.58, for a total value of $126,403.84. Following the completion of the sale, the chief executive officer now owns 482,875 shares of the company's stock, valued at $6,074,567.50. The trade was a 2.04 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 27,348 shares of company stock valued at $356,349. Insiders own 3.90% of the company's stock.

SI-BONE Stock Performance

Shares of NASDAQ:SIBN traded up $2.52 during midday trading on Monday, reaching $16.24. 337,995 shares of the company's stock traded hands, compared to its average volume of 284,782. SI-BONE, Inc. has a one year low of $11.70 and a one year high of $21.64. The stock has a 50 day moving average of $13.68 and a 200 day moving average of $14.21. The company has a market cap of $681.07 million, a price-to-earnings ratio of -17.65 and a beta of 1.16. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.